A phase 1, single-center, open label, up to two-part, single dose study to evaluate the pharmacokinetics, safety, tolerability, effect of refrigerated storage on taste of tecovirimat pediatric formulation prototype(s) for oral suspension in healthy adult subjects
Latest Information Update: 08 Mar 2023
At a glance
- Drugs Tecovirimat (Primary) ; Tecovirimat
- Indications Monkeypox; Orthopoxvirus infections; Smallpox; Vaccinia
- Focus Pharmacokinetics
- Sponsors SIGA Technologies
- 06 Oct 2022 Status changed from active, no longer recruiting to completed.
- 08 Jun 2022 Planned End Date changed from 8 Jun 2022 to 9 Oct 2022.
- 23 Sep 2021 Planned initiation date changed to 1 Dec 2021.